Background incidence of serum creatinine threshold rises in a predominantly female clinical trial population without underlying renal disease

A sustained increase in Cr of 0.5 mg/dl from baseline as a stopping criteria for potential nephrotoxicity would have resulted in study drug cessation in approximately 1 in 1000 participants in this selected clinical trial population and would not have caused undue clinical trial attrition.